<DOC>
	<DOCNO>NCT02085863</DOCNO>
	<brief_summary>This single center , randomize , double blind , placebo control , 2-way crossover drug-drug interaction ( DDI ) study assess effect laquinimod PK PD ethinylestradiol ( EE ) levonorgestrel ( LNG ) commonly use oral contraceptive combination .</brief_summary>
	<brief_title>A Phase I Study Young Healthy Women Investigate Effects Laquinimod Standard Oral Contraceptive When Both Treatments Are Given Together</brief_title>
	<detailed_description />
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<criteria>1 . Premenopausal woman age 18 40 year , healthy , nonpregnant planning pregnancy within study period . 2 . Women childbearing potential willing continuously use oral contraceptive ( OC ) product contain EE 30 μg LNG 150 μg least commencement last normal period prior first dose study medication total 4 consecutive cycle . 3 . Willing use double barrier method contraception ( condom diaphragm spermicide ) screen 30 day last laquinimod/placebo treatment . During administration OC , double barrier method also use . 4 . Body Mass Index range 1830 kg/m2 , inclusive . 5 . Must good health determine medical history , electrocardiogram ( ECG ) , vital sign , physical gynecological examination , clinical laboratory test . 6 . Must regular menstrual cycle 25 35 day ( 283/+7days ) precede 3 month prior screen . 7 . Subjects must able understand requirement study willing comply requirement study ( eg , dietary , exercise , tobacco alcohol restriction ) provide write informed consent participate study . 1 . Subjects smoke frequency , smoke last 6 month , plan start smoking study , tobacco user , subject currently use nicotine product ( patch , gum , etc . ) subject positive urine cotinine test screen and/or day 7 . 2 . Subjects know drug hypersensitivity laquinimod , one excipients ( ie , mannitol , meglumine , sodium stearyl fumarate ) . 3 . Subjects significant food/drug allergy discretion investigator . 4 . Subjects pregnant lactating . 5 . Subjects one follow condition note amount time prior screening time screen day 7 : Major trauma surgery past 2 month . Acute infection within 2 week ( 14 day ) . 6 . Any malignancy , exclude basal cell carcinoma , prior randomization . 7 . Subjects condition possibly interfere drug absorption , distribution , metabolism , excretion . 8 . Subjects suffer , history , one following : cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , neurological , immunological , psychiatric disorder ( ) , history illness , opinion Investigator , might pose additional risk subject participation study confound result study . 9 . Subjects suffer condition OC contra indicate recommend . 10 . Subjects use patches/intrauterine device/injectable hormonal contraception within 6 month prior screen . 11 . History irregular menstruation . 12 . Subjects clinically relevant abnormality ( judged investigator ) serum electrolytes complete blood count . 13 . Serum level ≥2× upper limit normal alanine aminotransferase aspartate aminotransferase gammaglutamyltransferase alkaline phosphatase direct bilirubin . 14 . Subjects use one forbidden drug food follow : Excessive amount ( define daily intake alcohol &gt; 40 g ) alcoholic beverage ( eg , beer , wine , distilled spirit ) , history alcohol abuse , unwilling comply restrict use alcoholic beverage study . An investigational drug ( new chemical entity ) 90 day 5 halflives prior day 7 ( whichever longer ) . Any medication , include overthecounter medication herbal preparation , use within 14 day prior day 7 ( except occasional paracetamol/acetaminophen ibuprofen use OC ) . Any contraindicated concomitant medication accord OC labeling . Inducers inhibitor cytochrome P450 3A4 within 30 day prior day 7 . Subjects consume grapefruit , grapefruit juice , Seville oranges pomelocontaining product , within 14 day ( 2 week ) prior day 7 . 15 . Subjects positive urine drug test ( cocaine , amphetamine , barbiturate , opiate , benzodiazepine , tetrahydrocannabinol ) positive test ethanol screen day 7 . 16 . Subjects donate received blood , plasma , platelet transfusion 3 month prior day 7 , make donation 2 occasion within 12 month precede day 7 , plan donation study period 3 month follow study . 17 . Subjects positive screen test hepatitis B surface antigen , hepatitis C antibody , human immunodeficiency virus antibody screen . 18 . Subjects participate successfully complete study , opinion general practitioner investigator , follow reason : Subjects legal age consent mentally legally incapacitate , unable give consent reason . Subjects custody due administrative legal decision , tutelage , admit sanitarium social institution . Subjects unable contacted case emergency . Subjects employ Sponsor investigational site conduct study Any reason , discretion investigator .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>